Shots:

• AstraZeneca has signed a supply agreement with Cobra to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222- previously known as ChAdOx1 n-CoV-19
• The companies collaborated to provide large scale manufacturing capacity of the AZD1222 vaccine. Cobra will be manufacturing the vaccine with first deliveries to be initiated in the UK in Sep’2020
• The agreement is part of AstraZeneca's in-licensed program with the University of Oxford to ensure equitable supply of the vaccine across the globe- at no profit during the COVID-19 pandemic. The Cobra is a part of a consortium with the Jenner Institute- University of Oxford- and others- to ramp up the production of ChAdOx1 nCoV-19

Click here to read full press release/ article

Ref: AstraZeneca | Image: Twitter